Nichola Downs

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings et al. · Journal of Antimicrobial Chemotherapy · 2021 · 118 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Simon J. Crabb, Gareth Griffiths, Ellice Marwood et al. · Journal of Clinical Oncology · 2020 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders et al. · The Lancet Infectious Diseases · 2022 · 80 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

Simon J. Crabb, Alison Birtle, Karen Martin et al. · Investigational New Drugs · 2017 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17